Grail, INC 8-K filings

GRAIL, Inc. announced first quarter 2026 financial results, showcasing significant year-over-year growth in revenue and test volume, alongside strategic advancements in healthcare integration.

GRAIL, Inc. announced its Q4 and full-year 2025 financial results, alongside topline data from the NHS-Galleri trial and PATHFINDER 2 study, highlighting significant commercial growth and progress in multi-cancer early detection.

GRAIL, Inc. presented preliminary financial results for 2025 and strategic updates at the J.P. Morgan Healthcare Conference, highlighting significant growth in Galleri test adoption and a strengthened cash position.

GRAIL, Inc. established an At-The-Market (ATM) equity offering program to sell up to $300 million of common stock and filed for the resale of 3.9 million shares.

GRAIL, Inc. reported strong third-quarter 2025 financial results with significant revenue growth and increased Galleri test volumes, alongside positive clinical data and strategic partnerships.

GRAIL, Inc. announced a $325.0 million private placement financing with institutional investors, significantly extending its operational funding into 2030.

GRAIL, Inc. announced a $110 million private placement with Samsung C&T and Samsung Electronics, alongside strategic collaborations to commercialize its Galleri multi-cancer early detection test in Asia and explore broader health technology integrations.

GRAIL, Inc. has entered into an 11-year commercial lease for a new 75,556 square foot corporate headquarters in Sunnyvale, California, commencing October 2026.

GRAIL, Inc. reported a 22% year-over-year increase in Galleri revenue to $34.4 million and a significant 93% reduction in net loss for the second quarter of 2025, alongside positive clinical trial results.

GRAIL, Inc. announced the successful election of William Chase as a Class I Director and the ratification of Ernst & Young LLP as its independent auditor at its Annual Meeting of Stockholders held on May 29, 2025.

GRAIL Inc. has amended offer letters for key executives, Josh Ofman and Aaron Freidin, to enhance severance benefits under certain termination scenarios, including those related to a change in control.

GRAIL, Inc. announced its Q1 2025 financial results, highlighting a 22% year-over-year increase in U.S. Galleri revenue and positive top-line results from the NHS-Galleri trial.

GRAIL's 2024 revenue increased significantly, driven by a 45% surge in U.S. Galleri test revenue, alongside key milestones in clinical studies and commercial expansion.

GRAIL, Inc. presented a corporate update and preliminary financial information for the quarter and year ended December 31, 2024, at the 2025 J.P. Morgan Healthcare Conference, highlighting commercial growth, clinical validation, and strategic priorities.

GRAIL, Inc. announced a 52% year-over-year increase in Galleri test revenue, reaching $25.4 million, and surpassing 250,000 tests sold since launch, while also reporting a net loss of $125.7 million for the third quarter of 2024.

GRAIL, Inc. has appointed Sarah Krevans to its Board of Directors, effective immediately, adding her extensive healthcare leadership experience to the company.

GRAIL, Inc. reported a 43% year-over-year revenue increase to $32.0 million in the second quarter of 2024 and announced a strategic restructuring to extend its cash runway into 2028.

GRAIL, Inc. will release its financial results for the quarter ended June 30, 2024, on August 13, 2024, following its separation from Illumina.

GRAIL, Inc. has amended its initial 8-K filing to provide additional details regarding its 2024 Incentive Award Plan, Employee Stock Purchase Plan, and Non-Employee Director Compensation Program following its separation from Illumina.

GRAIL, Inc. expects to record an $888.9 million goodwill impairment charge and a significant impairment charge for in-process research and development (IPR&D) intangible assets in the second quarter of 2024 following its spin-off from Illumina.

GRAIL Inc. has successfully separated from Illumina, becoming an independent, publicly traded company with its common stock set to trade on the Nasdaq Global Select Market under the ticker symbol GRAL.

GRAIL, LLC has converted to a corporation named GRAIL, Inc. and established a board of directors, appointing Charles Dadswell, Ankur Dhingra, and William Chase as directors effective June 11, 2024.

GRAIL, LLC clarifies the distribution date and trading details for its spin-off from Illumina, Inc., with the distribution expected on June 24, 2024.

GRAIL, LLC will be converted into GRAIL, Inc. and spun off from Illumina, becoming an independent, publicly traded company on June 24, 2024.